Overall, this case highlights the favorable clinical activity of T-DXd in managing HER2-low advanced breast cancer while underscoring the challenges of balancing efficacy and toxicity—particularly ILD—among elderly patients with multiple comorbidities. The gene discussed is ERBB2; the disease is interstitial lung disease.